Hudson Bay Capital Management LP Acquires Shares of 102,185 Disc Medicine, Inc. $IRON

Hudson Bay Capital Management LP acquired a new stake in shares of Disc Medicine, Inc. (NASDAQ:IRON) in the third quarter, HoldingsChannel.com reports. The fund acquired 102,185 shares of the company’s stock, valued at approximately $6,752,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Aster Capital Management DIFC Ltd purchased a new position in shares of Disc Medicine in the third quarter worth $38,000. Avanza Fonder AB boosted its position in Disc Medicine by 54.0% during the 3rd quarter. Avanza Fonder AB now owns 1,668 shares of the company’s stock valued at $110,000 after buying an additional 585 shares during the period. Ameritas Investment Partners Inc. grew its holdings in Disc Medicine by 8.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company’s stock worth $133,000 after acquiring an additional 206 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Disc Medicine by 15,137.5% during the third quarter. Russell Investments Group Ltd. now owns 2,438 shares of the company’s stock worth $161,000 after purchasing an additional 2,422 shares during the period. Finally, Tower Research Capital LLC TRC grew its stake in shares of Disc Medicine by 383.0% in the second quarter. Tower Research Capital LLC TRC now owns 3,975 shares of the company’s stock worth $211,000 after purchasing an additional 3,152 shares during the last quarter. Institutional investors own 83.70% of the company’s stock.

Insider Activity

In related news, CEO John D. Quisel sold 13,264 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total value of $833,775.04. Following the completion of the transaction, the chief executive officer directly owned 226,064 shares in the company, valued at $14,210,383.04. The trade was a 5.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Pamela Stephenson sold 5,531 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total value of $347,678.66. Following the completion of the transaction, the insider directly owned 80,998 shares in the company, valued at $5,091,534.28. This trade represents a 6.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 54,522 shares of company stock valued at $3,579,979. Company insiders own 3.64% of the company’s stock.

Disc Medicine Stock Performance

Shares of Disc Medicine stock opened at $58.17 on Friday. The stock has a market cap of $2.20 billion, a price-to-earnings ratio of -9.71 and a beta of 0.87. The firm’s 50-day moving average is $69.17 and its 200 day moving average is $75.61. Disc Medicine, Inc. has a 1 year low of $30.82 and a 1 year high of $99.50. The company has a debt-to-equity ratio of 0.04, a current ratio of 21.94 and a quick ratio of 21.94.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Thursday, February 26th. The company reported ($1.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.69) by $0.07. The firm had revenue of ($19.88) million for the quarter, compared to the consensus estimate of $0.15 million. Sell-side analysts anticipate that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on IRON. TD Cowen reiterated a “buy” rating on shares of Disc Medicine in a research report on Friday, December 19th. UBS Group reiterated an “overweight” rating on shares of Disc Medicine in a report on Thursday, January 15th. Morgan Stanley set a $75.00 target price on Disc Medicine in a research report on Tuesday, February 17th. Wedbush lowered their target price on Disc Medicine from $110.00 to $88.00 and set an “outperform” rating for the company in a research note on Tuesday, February 17th. Finally, BMO Capital Markets dropped their price target on Disc Medicine from $120.00 to $100.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 17th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Disc Medicine has a consensus rating of “Moderate Buy” and a consensus price target of $104.80.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.